GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...
GSK rises Wednesday, outperforms market
GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.
Investor's Business Daily on MSN3h
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK stock rocketed Wednesday after the pharma titan raised its 2031 sales outlook to north of $50 billion.Please watch the ...
GSK outlines 2025 growth driven by specialty medicines and new product launches
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
STAT4h
This week in biotech earnings so far
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
FiercePharma4h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
The Impact and Trends of Review Designations in the Pharmaceutical Industry
The "Pharmaceutical Review Designations: Trends and Industry Insights" report has been added to ResearchAndMarkets.com's offering.This report investigates review designations in the pharmaceutical ...
Annual core operating profit increases for British pharma GSK
Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...
GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook
The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...
European markets open mixed ahead of more earnings reports; GSK up 6%
European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.
GSK Pharma put volume heavy and directionally bearish
Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts. The Put/Call ...
Vanda Pharmaceuticals And Anaptys Announce Exclusive Global License Agreement For Vanda To Develop And Commercialize Imsidolimab, An IL-36R Antagonist
Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...